Cardiorenal benefits of empagliflozin in patients with chronic kidney disease continue for up to 12 months after discontinuation but diminish over time. Long-term use may be necessary to maximize ...

In the active trial, patients with chronic kidney disease were randomly assigned to receive either empagliflozin (10 mg once daily) or matching placebo and were followed for a median of 2 years ...